Treatments for Stage IV Colon Cancer and Overall Survival

Area of Science:

• Oncology
• Surgical Oncology
• Gastrointestinal Oncology

Background:

• The role of primary tumor resection (PTR) for asymptomatic stage IV colon cancer with unresectable metastases is debated.
• There is a growing trend away from surgical resection in these patients.
• Understanding treatment impacts on survival is crucial for optimizing care.

Purpose of the Study:

• To analyze trends in stage IV colon cancer treatment.
• To evaluate the impact of different treatment strategies on long-term mortality.
• To identify factors influencing the use of postoperative chemotherapy.

Main Methods:

• Analysis of the National Cancer Data Base (2006-2012) for stage IV colon cancer patients.
• Categorization of treatments: PTR + chemotherapy, PTR only, chemotherapy only, no treatment.
• Statistical analysis using Cox regression for survival and logistic regression for chemotherapy receipt.

Main Results:

• 22% received PTR and chemotherapy, 37.5% chemotherapy only, 11.9% PTR only, 28.6% no treatment.
• No treatment group had the highest mortality hazard, followed by PTR only and chemotherapy only, compared to PTR + chemotherapy.
• Older patients and those with more comorbidities were less likely to receive postoperative chemotherapy.

Conclusions:

• Primary tumor resection with postoperative chemotherapy offers a survival benefit for stage IV colon cancer with unresectable metastases.
• Postoperative chemotherapy should be utilized more frequently when clinically appropriate.
• Optimizing treatment strategies can improve outcomes for advanced colon cancer.